Vše

Co hledáte?

Vše
Projekty
Výsledky výzkumu
Subjekty

Rychlé hledání

  • Projekty podpořené TA ČR
  • Významné projekty
  • Projekty s nejvyšší státní podporou
  • Aktuálně běžící projekty

Chytré vyhledávání

  • Takto najdu konkrétní +slovo
  • Takto z výsledků -slovo zcela vynechám
  • “Takto můžu najít celou frázi”

Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action

Identifikátory výsledku

  • Kód výsledku v IS VaVaI

    <a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68081707%3A_____%2F16%3A00471983" target="_blank" >RIV/68081707:_____/16:00471983 - isvavai.cz</a>

  • Nalezeny alternativní kódy

    RIV/61989592:15310/16:33161172

  • Výsledek na webu

    <a href="http://dx.doi.org/10.1039/c5sc04205d" target="_blank" >http://dx.doi.org/10.1039/c5sc04205d</a>

  • DOI - Digital Object Identifier

    <a href="http://dx.doi.org/10.1039/c5sc04205d" target="_blank" >10.1039/c5sc04205d</a>

Alternativní jazyky

  • Jazyk výsledku

    angličtina

  • Název v původním jazyce

    Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action

  • Popis výsledku v původním jazyce

    Our study demonstrates that Pt(IV) derivative of cisplatin, with two axial PhB ligands, ctc-[Pt(NH3)(2)(PhB)(2)Cl-2], is a very potent cytotoxic agent against many different human cancer cell lines and is up to 100 fold more potent than cisplatin, and significantly more potent than the Pt(IV) derivatives of cisplatin with either two hydroxido, two acetato or two valproato ligands. The high potency of this compound (and some others) is due to several factors including enhanced internalization, probably driven by "synergistic accumulation" of both the Pt moiety and the phenylbutyrate, that correlates with enhanced DNA binding and cytotoxicity. ctc-[Pt(NH3)(2)(PhB)(2)Cl-2] inhibits 60-70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB. Mechanistically, ctc[Pt(NH3)(2)(PhB)(2)Cl-2] induces activation of caspases (3 and 9) triggering apoptotic signaling via the mitochondrial pathway. Data also suggest that the antiproliferative effect of ctc-[Pt(NH3)(2)(PhB)(2)Cl-2] may not depend of p53. Pt(IV) derivatives of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs. ctc-[Pt(NH3)(2)(PhB)(2)Cl-2] is significantly more potent than its valproate analog ctc-[Pt(NH3)(2)(VPA)(2)Cl-2]. These compounds combine multiple effects such as efficient uptake of both Pt and PhB with DNA binding, HDAC inhibition and activation of caspases to effectively kill cancer cells.

  • Název v anglickém jazyce

    Pt(IV) derivatives of cisplatin and oxaliplatin with phenylbutyrate axial ligands are potent cytotoxic agents that act by several mechanisms of action

  • Popis výsledku anglicky

    Our study demonstrates that Pt(IV) derivative of cisplatin, with two axial PhB ligands, ctc-[Pt(NH3)(2)(PhB)(2)Cl-2], is a very potent cytotoxic agent against many different human cancer cell lines and is up to 100 fold more potent than cisplatin, and significantly more potent than the Pt(IV) derivatives of cisplatin with either two hydroxido, two acetato or two valproato ligands. The high potency of this compound (and some others) is due to several factors including enhanced internalization, probably driven by "synergistic accumulation" of both the Pt moiety and the phenylbutyrate, that correlates with enhanced DNA binding and cytotoxicity. ctc-[Pt(NH3)(2)(PhB)(2)Cl-2] inhibits 60-70% HDAC activity in cancer cells, at levels below the IC50 values of PhB, suggesting synergism between Pt and PhB. Mechanistically, ctc[Pt(NH3)(2)(PhB)(2)Cl-2] induces activation of caspases (3 and 9) triggering apoptotic signaling via the mitochondrial pathway. Data also suggest that the antiproliferative effect of ctc-[Pt(NH3)(2)(PhB)(2)Cl-2] may not depend of p53. Pt(IV) derivatives of cisplatin with either two axial PhB or valproate ligands are more potent than their oxaliplatin analogs. ctc-[Pt(NH3)(2)(PhB)(2)Cl-2] is significantly more potent than its valproate analog ctc-[Pt(NH3)(2)(VPA)(2)Cl-2]. These compounds combine multiple effects such as efficient uptake of both Pt and PhB with DNA binding, HDAC inhibition and activation of caspases to effectively kill cancer cells.

Klasifikace

  • Druh

    J<sub>x</sub> - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

  • CEP obor

    BO - Biofyzika

  • OECD FORD obor

Návaznosti výsledku

  • Projekt

    <a href="/cs/project/GA14-21053S" target="_blank" >GA14-21053S: Mechanistické studie o duálním cílení DNA a deacetylázy histonů bifunkčními inhibitory</a><br>

  • Návaznosti

    I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Ostatní

  • Rok uplatnění

    2016

  • Kód důvěrnosti údajů

    S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Údaje specifické pro druh výsledku

  • Název periodika

    Chemical Science

  • ISSN

    2041-6520

  • e-ISSN

  • Svazek periodika

    7

  • Číslo periodika v rámci svazku

    3

  • Stát vydavatele periodika

    GB - Spojené království Velké Británie a Severního Irska

  • Počet stran výsledku

    11

  • Strana od-do

    2381-2391

  • Kód UT WoS článku

    000371021900096

  • EID výsledku v databázi Scopus